ESSA Pharma EPIX Corporate Presentation August 2022

ESSA Pharma is a clinical-stage biopharmaceutical company developing first-in-class N-terminal domain inhibitors for prostate and androgen-driven cancers. The presentation outlines the company's lead candidate EPI-7386, including Phase 1 monotherapy and Phase 1/2 combination studies, with clinical programs designed for patients with metastatic castration-resistant prostate cancer.